xmlui.ArtifactBrowser.ItemViewer.show_simple

dc.contributor.authorItoh, Megumi-
dc.contributor.authorValle, Suiane Costa Negreiros do-
dc.contributor.authorFarias, Sâmela-
dc.contributor.authorSouza, Thayna Maria Holanda de-
dc.contributor.authorViana, Giselle Maria Rachid-
dc.contributor.authorLucchi, Naomi W-
dc.contributor.authorChenet, Stella-
dc.contributor.authorMarchesini, Paola-
dc.contributor.authorPóvoa, Marinete Marins-
dc.contributor.authorSantelli, Ana carolina Faria e Silva-
dc.contributor.authorOliveira, Alexandre Macedo de-
dc.date.accessioned2018-02-28T12:50:20Z-
dc.date.available2018-02-28T12:50:20Z-
dc.date.issued2018-
dc.identifier.citationITOH, Megumi et al. Efficacy of Artemether-Lumefantrine for uncomplicated plasmodium falciparum malaria in Cruzeiro do Sul, Brazil, 2016. American Journal of Tropical Medicine and Hygiene, v. 98, n. 1, p. 88-94, Jan. 2018.pt_BR
dc.identifier.issn0002-9637-
dc.identifier.urihttp://patua.iec.gov.br//handle/iec/3054-
dc.description.abstractWe evaluated the therapeutic efficacy of artemether–lumefantrine (AL) fixed-dose combination to treat uncomplicated Plasmodium falciparum malaria in Cruzeiro do Sul, Acre State, in the Amazon region of Brazil. Between December 2015 and May 2016, we enrolled 79 patients, 5–79 years old with fever or history of fever in the previous 48 hours and P. falciparum monoinfection confirmed by microscopy. Attempts were made to provide direct observation or phone reminders for all six doses of AL, and patients were followed-up for 28 days. AL was well tolerated, with no adverse events causing treatment interruption. All but one of the 74 patients who completed the 28-day follow-up had an adequate clinical and parasitologic response = 98.6% (95% CI: 93.2-100%). We could not amplify the one isolate of the case with recurrent infection to differentiate between recrudescence and reinfection. Five (6.3%) patients demonstrated persistent asexual parasitemia on Day 3, but none met definition for early treatment failure. We found no mutations in selected kelch13 gene domains, known to be associated with artemisinin resistance in P. falciparum isolates from Day 0. These results strongly support the continued use of AL as a first-line therapy for uncomplicated P. falciparum malaria in Acre. Routine monitoring of in vivo drug efficacy coupled with molecular surveillance of drug resistance markers remains critical.pt_BR
dc.language.isoengpt_BR
dc.publisherAmerican Society of Tropical Medicine and Hygienept_BR
dc.rightsAcesso Abertopt_BR
dc.titleEfficacy of Artemether-Lumefantrine for uncomplicated plasmodium falciparum malaria in Cruzeiro do Sul, Brazil, 2016pt_BR
dc.typeArtigopt_BR
dc.subject.decsPrimaryMalariapt_BR
dc.subject.decsPrimaryPlasmodium falciparum / parasitologiapt_BR
dc.subject.decsPrimaryAntimaláricos / farmacologiapt_BR
dc.subject.decsPrimaryRegião Norte (BR)pt_BR
dc.subject.decsPrimaryAcre (AC)pt_BR
dc.subject.decsPrimaryCruzeiro do Sul (AC)pt_BR
dc.creator.affilliationCenters for Disease Control & Prevention. Center for Global Health. Division of Parasitic Diseases and Malaria. Malaria Branch. Atlanta, GA USA.pt_BR
dc.creator.affilliationAcre State Health Secretariat. Cruzeiro do Sul, AC, Brazil.pt_BR
dc.creator.affilliationAcre State Health Secretariat. Cruzeiro do Sul, AC, Brazil.pt_BR
dc.creator.affilliationAcre State Health Secretariat. Cruzeiro do Sul, AC, Brazil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Ananindeua, PA, Brasil.pt_BR
dc.creator.affilliationCenters for Disease Control & Prevention. Center for Global Health. Division of Parasitic Diseases and Malaria. Malaria Branch. Atlanta, GA USA.pt_BR
dc.creator.affilliationCenters for Disease Control & Prevention. Center for Global Health. Division of Parasitic Diseases and Malaria. Malaria Branch. Atlanta, GA USA.pt_BR
dc.creator.affilliationBrazilian Ministry of Health. National Malaria Control Program. Brasilia, DF, Brazil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Ananindeua, PA, Brasil.pt_BR
dc.creator.affilliationFundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sérgio Arouca. Rio de Janeiro, RJ, Brazil.pt_BR
dc.creator.affilliationCenters for Disease Control & Prevention. Center for Global Health. Division of Parasitic Diseases and Malaria. Malaria Branch. Atlanta, GA USA.pt_BR
dc.identifier.doi10.4269/ajtmh.17-0623-


xmlui.dri2xhtml.METS-1.0.item-files-head

Thumbnail

xmlui.ArtifactBrowser.ItemViewer.head_parent_collections

xmlui.ArtifactBrowser.ItemViewer.show_simple